CN101862305A - Ambroxol hydrochloride sustained-release pellet and preparation method - Google Patents
Ambroxol hydrochloride sustained-release pellet and preparation method Download PDFInfo
- Publication number
- CN101862305A CN101862305A CN200910082237A CN200910082237A CN101862305A CN 101862305 A CN101862305 A CN 101862305A CN 200910082237 A CN200910082237 A CN 200910082237A CN 200910082237 A CN200910082237 A CN 200910082237A CN 101862305 A CN101862305 A CN 101862305A
- Authority
- CN
- China
- Prior art keywords
- release
- slow
- release micro
- pill
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 238000013268 sustained release Methods 0.000 title claims abstract description 13
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 13
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 title claims description 17
- 229960000985 ambroxol hydrochloride Drugs 0.000 title claims description 17
- 239000008188 pellet Substances 0.000 title abstract description 6
- 238000000576 coating method Methods 0.000 claims abstract description 23
- 239000011248 coating agent Substances 0.000 claims abstract description 16
- 239000006187 pill Substances 0.000 claims description 25
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 229960003943 hypromellose Drugs 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 239000011247 coating layer Substances 0.000 claims description 7
- 239000010410 layer Substances 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000007779 soft material Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000004014 plasticizer Substances 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 3
- 238000004132 cross linking Methods 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 238000013265 extended release Methods 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 abstract description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 208000026435 phlegm Diseases 0.000 abstract description 3
- 229960005174 ambroxol Drugs 0.000 abstract description 2
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 208000030090 Acute Disease Diseases 0.000 abstract 1
- 208000014085 Chronic respiratory disease Diseases 0.000 abstract 1
- 230000003578 releasing effect Effects 0.000 description 6
- 206010036790 Productive cough Diseases 0.000 description 3
- 208000018569 Respiratory Tract disease Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000003405 delayed action preparation Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000420 mucociliary effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the composition of an ambroxol HCl-containing sustained-release pellet and a preparation method. The sustained-release pellet consists of two parts which are a quick-release pellet core and a sustained-release coating film respectively, can achieve the effect of long-term release approaching to zero-order release, is mainly used for treating acute and chronic respiratory diseases, and is a medicament of first choice for dispelling phlegm.
Description
Technical field
The present invention relates to a kind of composition and preparation method that contains the slow-release micro-pill of ambroxol hydrochloride, this slow-release micro-pill is made up of the rapid release ball heart and slow release coatings two parts, can reach the long-term releasing effect that discharges near zero level, being mainly used in the treatment of acute and chronic respiratory tract disease, is the choice drug that eliminates the phlegm.
Background technology
Ambroxol hydrochloride Ambroxol HCl proves in clinical trial: this product scalable serosity and mucous secretion, promote the synthetic of lung surface active material, and strengthen fibre swing, increase the removing ability of mucociliary transportation system.These product also can increase the respiratory tract liquid measure, reduce mucous secretion, can promote the secretion and the bronchus ciliary movement of pulmonary surfactant, make expectorant be easy to expectoration.Be applicable to acute, chronic respiratory tract disease that companion's sputum is secreted undesired and expectoration dysfunction clinically.The for example treatment of the prophylactic treatment of chronic bronchitis acute exacerbation, asthmatic bronchitis, bronchiectasis and san bronchial asthma, postoperative pulmonary complication and premature infant and new-born baby respiratory distress syndrome.Ambroxol hydrochloride oral absorbs rapidly, eliminates half-life 2～3hr, and best dosage regimen is every day 1～2 time, is to improve compliance of patients, farthest reduces individual patient difference simultaneously, and the ambroxol hydrochloride controlled release preparation is studied.The sustained-release preparation that allows to be administered once every day is different from ordinary preparation by the release that prolongs active substance.
Patent CN100370977C has protected a kind of slow releasing tablet of ambroxol-hydrochloride-containing active component, though can reach the effect of slow release, can't reach releasing effect near zero level, and because the interior environment of human stomach, slow releasing tablet is difficult to reach uniform release, and the diversity of release is bigger; Patent CN1546008A has protected a kind of ambroxol hydrochloride liquid slow releasing preparation and preparation method thereof, though can reach uniform release at gastric, packing cost is higher, and transportation inconvenience; Patent CN1415287A discloses a kind of ambroxol hydrochloride osmotic pump type controlled release preparation and preparation method thereof, though can reach even release at gastric, and convenient transportation, in preparation process, need special equipment, production cost height, difficult experiment industrialization.
The invention provides a kind of ambroxol hydrochloride sustained-release pellet that can reach,, can be dispersed into micropill at gastric with capsular form administration near the zero level releasing effect, can reach comparatively uniformly and discharge, and production cost is comparatively moderate, industrialization level height, convenient transportation.
Summary of the invention
The invention provides a kind of slow-release micro-pill that contains ambroxol hydrochloride, this slow-release micro-pill is made up of the rapid release ball heart and coatings, and coatings wherein comprises contagion gown layer and sustained-release coating layer again.
This slow-release micro-pill provided by the invention, the rapid release ball heart is made up of 25～40% ambroxol hydrochloride and pharmaceutic adjuvant.
This slow-release micro-pill provided by the invention, pharmaceutic adjuvant comprises filler, disintegrating agent and binding agent.
This slow-release micro-pill provided by the invention, filler are lactose, starch, microcrystalline Cellulose, mannitol, and its shared percentage by weight is 60～70%.
This slow-release micro-pill provided by the invention, disintegrating agent are cross-linking sodium carboxymethyl cellulose, crosslinked carboxymethyl fecula sodium, polyvinylpolypyrrolidone or low-substituted hydroxypropyl methylcellulose, and its shared weight percent is 2～8%.
This slow-release micro-pill provided by the invention, the percentage by weight of contagion gown layer in slow-release micro-pill is 2～6%, the hypromellose by 5～8%, 0.5% Polyethylene Glycol and Pulvis Talci are formed.
This slow-release micro-pill provided by the invention, the percentage by weight of sustained-release coating layer in slow-release micro-pill is 8～20%, the You Teqi by 8～15%, 0.5% plasticizer and Pulvis Talci are formed.
This slow-release micro-pill provided by the invention, its preparation method is:
1) preparation of the rapid release ball heart: with the raw material of recipe quantity and filler, disintegrating agent mixing,, be prepared into the micropill that diameter is 1mm～2mm, dry in the baking oven, sieve out the ball heart that is of moderate size with extruding spheronizator with suitable amount of adhesive system soft material;
2) bag contagion gown: hypromellose, Polyethylene Glycol and the Pulvis Talci of recipe quantity are placed 50% pure water, stir, it is fully dissolved or disperses, coating increases weight to 2～6%;
3) bag extended release coatings: You Teqi, plasticizer and the Pulvis Talci of recipe quantity are placed 95% ethanol, stir, it is fully dissolved or disperses, coating increases weight to 8～20%;
4) with the micropill fill capsule behind the coating.
This slow-release micro-pill provided by the invention is mainly used in the treatment of acute and chronic respiratory tract disease, is the choice drug that eliminates the phlegm
The specific embodiment
Specifying the present invention in conjunction with the embodiments, but be not limited to following embodiment.Wherein " % " is meant " weight % ".
Embodiment 1
The preparation of the ball heart
Preparation technology:
Ambroxol hydrochloride and lactose, crosslinked carboxymethyl fecula sodium, microcrystalline Cellulose mixing, the polyvidone aqueous solution with 10% is a binding agent system soft material, prepares micropill with extruding spheronizator, the micropill about diameter 1mm is sieved out in the oven dry of spending the night, as the ball heart.
The contagion gown layer
Hypromellose, Polyethylene Glycol and the Pulvis Talci of recipe quantity are placed 50% pure water, stir, it is fully dissolved or disperses, coating increases weight to 2%.
Sustained-release coating layer
You Teqi, triethyl citrate and the Pulvis Talci of recipe quantity are placed 95% ethanol, stir, it is fully dissolved or disperses, coating increases weight to 8%;
With the micropill fill capsule behind the coating, promptly.
Embodiment 2
The preparation of the ball heart
Preparation technology:
Ambroxol hydrochloride and mannitol, cross-linking sodium carboxymethyl cellulose, microcrystalline Cellulose mixing, the hypromellose aqueous solution with 8% is a binding agent system soft material, prepares micropill with extruding spheronizator, the micropill about diameter 1mm is sieved out in the oven dry of spending the night, as the ball heart.
The contagion gown layer
Hypromellose, Polyethylene Glycol and the Pulvis Talci of recipe quantity are placed 50% pure water, stir, it is fully dissolved or disperses, coating increases weight to 4%.
Sustained-release coating layer
You Teqi, dibutyl phthalate and the Pulvis Talci of recipe quantity are placed 95% ethanol, stir, it is fully dissolved or disperses, coating increases weight to 15%;
With the micropill fill capsule behind the coating, promptly.
Embodiment 3
The preparation of the ball heart
Preparation technology:
Ambroxol hydrochloride and starch, polyvinylpolypyrrolidone, microcrystalline Cellulose mixing, the starch slurry with 10% are binding agent system soft material, prepare micropill with extruding spheronizator, and the micropill about diameter 1mm is sieved out in the oven dry of spending the night, as the ball heart;
The contagion gown layer
Hypromellose, Polyethylene Glycol and the Pulvis Talci of recipe quantity are placed 50% pure water, stir, it is fully dissolved or disperses, coating increases weight to 6%.
Sustained-release coating layer
You Teqi, dioctyl phthalate and the Pulvis Talci of recipe quantity are placed 95% ethanol, stir, it is fully dissolved or disperses, coating increases weight to 15%;
With the micropill fill capsule behind the coating, promptly.
Embodiment 4
Get the sample of embodiment 1 preparation, detect its release in vitro degree according to 2005 editions officinal methods, its release profiles as shown in Figure 1.
As can be seen from Figure, this product release in 4 hours reaches maximum, and the release in vitro before 4 hours can reach zero level substantially and discharge, and meets officinal regulation.
Claims (9)
1. a slow-release micro-pill that contains ambroxol hydrochloride is characterized in that being made up of the rapid release ball heart and coatings.
2. slow-release micro-pill according to claim 1 is characterized in that the described rapid release ball heart is made up of 25～40% ambroxol hydrochloride and pharmaceutic adjuvant.
3. slow-release micro-pill according to claim 2 is characterized in that described pharmaceutic adjuvant comprises filler, disintegrating agent and binding agent.
4. slow-release micro-pill according to claim 3 is characterized in that described filler is lactose, starch, microcrystalline Cellulose, mannitol, and its shared percentage by weight is 60～70%.
5. slow-release micro-pill according to claim 3 is characterized in that described disintegrating agent is cross-linking sodium carboxymethyl cellulose, crosslinked carboxymethyl fecula sodium, polyvinylpolypyrrolidone or low-substituted hydroxypropyl methylcellulose, and its shared weight percent is 2～8%.
6. slow-release micro-pill according to claim 1 is characterized in that described coatings is made up of contagion gown layer and sustained-release coating layer.
7. slow-release micro-pill according to claim 6 is characterized in that the percentage by weight of described contagion gown layer in slow-release micro-pill is 2～6%, and the hypromellose by 5～8%, 0.5% Polyethylene Glycol and Pulvis Talci are formed.
8. slow-release micro-pill according to claim 6 is characterized in that the percentage by weight of described sustained-release coating layer in slow-release micro-pill is 8～20%, and the You Teqi by 8～15%, 0.5% plasticizer and Pulvis Talci are formed.
9. slow-release micro-pill according to claim 1, its preparation method is:
1) preparation of the rapid release ball heart: with the raw material of recipe quantity and filler, disintegrating agent mixing,, be prepared into the micropill that diameter is 1mm～2mm, dry in the baking oven, sieve out the ball heart that is of moderate size with extruding spheronizator with suitable amount of adhesive system soft material;
2) bag contagion gown: hypromellose, Polyethylene Glycol and the Pulvis Talci of recipe quantity are placed 50% pure water, stir, it is fully dissolved or disperses, coating increases weight to 2～6%;
3) bag extended release coatings: You Teqi, plasticizer and the Pulvis Talci of recipe quantity are placed 95% ethanol, stir, it is fully dissolved or disperses, coating increases weight to 8～20%;
4) with the micropill fill capsule behind the coating.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910082237.8A CN101862305B (en) | 2009-04-20 | 2009-04-20 | Ambroxol hydrochloride sustained-release pellet and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910082237.8A CN101862305B (en) | 2009-04-20 | 2009-04-20 | Ambroxol hydrochloride sustained-release pellet and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101862305A true CN101862305A (en) | 2010-10-20 |
| CN101862305B CN101862305B (en) | 2014-05-07 |
Family
ID=42954369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910082237.8A Active CN101862305B (en) | 2009-04-20 | 2009-04-20 | Ambroxol hydrochloride sustained-release pellet and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101862305B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102266293A (en) * | 2011-07-21 | 2011-12-07 | 佛山市隆信医药科技有限公司 | Ambroxol hydrochloride sustained-release dry suspension and preparation method thereof |
| CN102772391A (en) * | 2012-08-16 | 2012-11-14 | 河南新帅克制药股份有限公司 | Ambroxol hydrochloride sustained release capsule and preparation method thereof |
| CN103054832A (en) * | 2012-12-26 | 2013-04-24 | 河南中帅医药科技发展有限公司 | Minocycline hydrochloride sustained-release capsule and preparation method thereof |
| CN103211789A (en) * | 2012-01-18 | 2013-07-24 | 北京天衡药物研究院 | Ambroxol hydrochloride film-controlled slow-release pellet capsule |
| CN105456202A (en) * | 2015-12-08 | 2016-04-06 | 青岛正大海尔制药有限公司 | Ambroxol and salbutamol pellet |
| CN107569473A (en) * | 2017-09-28 | 2018-01-12 | 南京易亨制药有限公司 | A kind of Sustained Release Ambroxol Hydrochloride Capsules and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR930011993B1 (en) * | 1991-12-23 | 1993-12-23 | 주식회사 럭키 | Process for preparing prolonged release of ambroxol preparation |
| US6251429B1 (en) * | 1991-12-11 | 2001-06-26 | Therapicon Slr | Programmed release ambroxol—HCl dosage forms |
| CN1415287A (en) * | 2002-11-28 | 2003-05-07 | 沈阳药科大学 | Hydrochloric ambroxol osmotic pump type controlled release formulation and its preparation method |
| CN1600296A (en) * | 2003-09-22 | 2005-03-30 | 北京德众万全药物技术开发有限公司 | Method for preparing tiny pellets of difficult soluble drugs and formulation containing the pellets |
| JP2008013480A (en) * | 2006-07-05 | 2008-01-24 | Sawai Pharmaceutical Co Ltd | Drug-containing micro-particle and method for producing the same |
| CN101288659A (en) * | 2007-04-18 | 2008-10-22 | 王雷波 | Floating type pellets in stomach and preparation method thereof |
-
2009
- 2009-04-20 CN CN200910082237.8A patent/CN101862305B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251429B1 (en) * | 1991-12-11 | 2001-06-26 | Therapicon Slr | Programmed release ambroxol—HCl dosage forms |
| KR930011993B1 (en) * | 1991-12-23 | 1993-12-23 | 주식회사 럭키 | Process for preparing prolonged release of ambroxol preparation |
| CN1415287A (en) * | 2002-11-28 | 2003-05-07 | 沈阳药科大学 | Hydrochloric ambroxol osmotic pump type controlled release formulation and its preparation method |
| CN1600296A (en) * | 2003-09-22 | 2005-03-30 | 北京德众万全药物技术开发有限公司 | Method for preparing tiny pellets of difficult soluble drugs and formulation containing the pellets |
| JP2008013480A (en) * | 2006-07-05 | 2008-01-24 | Sawai Pharmaceutical Co Ltd | Drug-containing micro-particle and method for producing the same |
| CN101288659A (en) * | 2007-04-18 | 2008-10-22 | 王雷波 | Floating type pellets in stomach and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 上海医药工业研究院药物制剂研究中心，等: "《药用辅料应用技术》", 31 July 2002, 中国医药科技出版社 * |
| 佟杰: "复方罗红霉素缓释微丸胶囊的研制", 《中国优秀硕士学位论文全文数据库》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102266293A (en) * | 2011-07-21 | 2011-12-07 | 佛山市隆信医药科技有限公司 | Ambroxol hydrochloride sustained-release dry suspension and preparation method thereof |
| CN102266293B (en) * | 2011-07-21 | 2013-05-01 | 佛山市隆信医药科技有限公司 | Ambroxol hydrochloride sustained-release dry suspension and preparation method thereof |
| CN103211789A (en) * | 2012-01-18 | 2013-07-24 | 北京天衡药物研究院 | Ambroxol hydrochloride film-controlled slow-release pellet capsule |
| CN103211789B (en) * | 2012-01-18 | 2017-07-11 | 北京天衡药物研究院有限公司 | Ambroxol hydrochloride film-controlled slow-release micro pill capsule |
| CN102772391A (en) * | 2012-08-16 | 2012-11-14 | 河南新帅克制药股份有限公司 | Ambroxol hydrochloride sustained release capsule and preparation method thereof |
| CN103054832A (en) * | 2012-12-26 | 2013-04-24 | 河南中帅医药科技发展有限公司 | Minocycline hydrochloride sustained-release capsule and preparation method thereof |
| CN105456202A (en) * | 2015-12-08 | 2016-04-06 | 青岛正大海尔制药有限公司 | Ambroxol and salbutamol pellet |
| CN107569473A (en) * | 2017-09-28 | 2018-01-12 | 南京易亨制药有限公司 | A kind of Sustained Release Ambroxol Hydrochloride Capsules and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101862305B (en) | 2014-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101862305B (en) | Ambroxol hydrochloride sustained-release pellet and preparation method | |
| WO2015028473A1 (en) | Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose | |
| WO2007074856A1 (en) | Method of producing solid preparation disintegrating in the oral cavity | |
| JP5534004B2 (en) | Orally disintegrating tablets | |
| Pan et al. | Novel compaction techniques with pellet-containing granules | |
| KR20120094882A (en) | Sustained-release pharmaceutical composition comprising mosapride or salt thereof | |
| CN104940156A (en) | Epalrestat enteric-coated and sustained-release tablets and preparation method thereof | |
| CN105496977A (en) | Succinic acid trelagliptin orally-disintegrating tablets and preparing method thereof | |
| CN104288774A (en) | Enteric coating, dimethyl fumarate enteric preparation, and preparation method thereof | |
| WO2014040548A1 (en) | Metoprolol sustained-release drug and preparation method therefor | |
| CN103976997A (en) | Hypoglycemic compound sustained-release capsule and preparation method thereof | |
| CN102579408B (en) | Doxycycline hydrochloride dual-release preparation and preparation method thereof | |
| CN1994285B (en) | Sustained release micro-pellet of guaifenesin and preparation process thereof | |
| CN102727452A (en) | Eszopiclone-containing particle and its preparation method | |
| CN1538837A (en) | Swallow tablet comprising paracetamol | |
| CN102349915B (en) | Acetaminophen, caffeine, chlorphenamine maleate, and vitamin C preparation and preparation method thereof | |
| JP5614445B2 (en) | Particulate pharmaceutical composition for oral administration | |
| CN103520129A (en) | Montelukast sodium pulse release preparation | |
| CN102266293B (en) | Ambroxol hydrochloride sustained-release dry suspension and preparation method thereof | |
| CN102846555B (en) | Solid preparation comprising pirfenidone as active component and application thereof | |
| CN102973533A (en) | Preparation method of famotidine gastric-floating-type pellet tablets | |
| WO2017047586A1 (en) | Tablet | |
| CN113908153B (en) | Buvaracetam pharmaceutical composition, preparation method and application thereof | |
| CN106620715B (en) | A Chinese medicinal composition for treating diabetes, and its preparation method | |
| CN101658507B (en) | Glyceryl guaiacolate and pseudoephedrine compound sustained release preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| DD01 | Delivery of document by public notice |
Addressee: Beijing D-Venturepharm Technology Development Co.,Ltd. Document name: Notification of an Office Action |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210113 Address after: 570314 no.279 Nanhai Avenue, Xiuying District, Haikou City, Hainan Province Patentee after: AVENTIS PHARMA (HAINAN) Co.,Ltd. Address before: 100097, Wanquan mansion, 3 Jin Zhuang, Haidian District, Beijing, Sijiqing Patentee before: BEIJING D-VENTUREPHARM TECHNOLOGY DEVELOPMENT Co.,Ltd. |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Song Xuemei Document name: Notice of conformity |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A sustained-release microsphere of ambroxol hydrochloride and its preparation method Granted publication date: 20140507 Pledgee: Sanya Rural Commercial Bank Co.,Ltd. Pledgor: AVENTIS PHARMA (HAINAN) Co.,Ltd. Registration number: Y2024980014810 |